Xingjuan Chao Sells 6,030 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 6,030 shares of the firm’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $18.00, for a total value of $108,540.00. Following the transaction, the chief executive officer directly owned 830,317 shares in the company, valued at approximately $14,945,706. This represents a 0.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Xingjuan Chao also recently made the following trade(s):

• On Tuesday, May 5th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $20.10, for a total value of $783,900.00.
• On Monday, April 6th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $18.40, for a total value of $717,600.00.
• On Tuesday, March 3rd, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $17.45, for a total value of $680,550.00.

CeriBell Price Performance

Shares of NASDAQ CBLL opened at $18.70 on Thursday. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.44 and a quick ratio of 10.01. The company has a market cap of $709.48 million, a PE ratio of -11.47 and a beta of 0.99. The stock has a fifty day moving average price of $19.08 and a 200 day moving average price of $19.29. CeriBell, Inc. has a 1-year low of $10.85 and a 1-year high of $24.33.

CeriBell (NASDAQ:CBLL) last released its earnings results on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.13). The firm had revenue of $26.49 million during the quarter, compared to analyst estimates of $26.09 million. CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%. Sell-side analysts forecast that CeriBell, Inc. will post -1.69 EPS for the current year.

Hedge Funds Weigh In On CeriBell

Several hedge funds have recently bought and sold shares of CBLL. Caitong International Asset Management Co. Ltd grew its holdings in CeriBell by 3,971.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after purchasing an additional 1,231 shares during the last quarter. Strs Ohio acquired a new position in shares of CeriBell during the 1st quarter worth $27,000. CWM LLC boosted its position in shares of CeriBell by 1,178.5% in the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after buying an additional 1,697 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after acquiring an additional 1,801 shares during the last quarter. Finally, Larson Financial Group LLC increased its holdings in CeriBell by 1,403.1% during the 4th quarter. Larson Financial Group LLC now owns 2,871 shares of the company’s stock valued at $63,000 after acquiring an additional 2,680 shares in the last quarter.

Wall Street Analyst Weigh In

CBLL has been the subject of several recent analyst reports. BTIG Research reissued a “buy” rating and issued a $30.00 price target on shares of CeriBell in a report on Wednesday, January 28th. Canaccord Genuity Group cut their price objective on CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, May 12th. Finally, Weiss Ratings lowered shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $22.20.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.